Researchers identify blood markers capable of predicting lung cancer risk up to five years in advance

Long before any visible sign of a tumor on imaging tests, internal processes in the lung can already indicate a predisposition. Cells react to factors such as smoking, pollution or genetic changes, generating inflammation that, although not a disease in itself, creates an environment conducive to the development of malignant conditions.
This biological movement, previously undetectable, was the focus of an investigation with more than a hundred researchers, under the coordination of Charles Swanton, from the Francis Crick Institute, in the United Kingdom. They were able to identify these signs in the blood, making it possible to predict the diagnosis within five years.
The discovery, published in the prestigious scientific journal Cell on June 25, is seen by scientists themselves as an initial milestone. It aims to develop a blood test capable of anticipating the type of cancer with the highest global mortality rate, paving the way for more effective prevention methods.
Stephen Stefani, a Brazilian oncologist from the Oncoclínicas group and member of the Americas Health Foundation, praised the research, classifying it as one of the most significant in cancer prevention in recent years. However, he emphasized that the journey from laboratory study to clinical application will still be long.
How proteins were identified for risk screening
The study began with a vast collection of frozen blood samples from the UK Biobank. This collection contains data and health histories from hundreds of thousands of British participants, collected long before any medical diagnosis was established.
Using an artificial intelligence algorithm, the team of researchers analyzed around 3,000 proteins found in these samples. Gradually, they were filtered, until a set of just 14 was considered relevant.
When these proteins were associated with factors such as the individuals’ age, smoking history and the existence of chronic obstructive pulmonary disease (COPD), the ability to predict the development of lung cancer in the following years proved to be superior to risk assessment models currently used in the medical field.
The consistency of this pattern was verified in eight different population groups, including regions such as the United States, China and Iceland, covering a total of more than 55 thousand participants.
In one of these groups, made up mainly of non-smokers in Taiwan, some of the same proteins also indicated an elevated risk. This detail is crucial, as conventional screening approaches often overlook individuals who have never smoked, revealing potential for expanding the reach of prevention.
The identification of a “signature” for the tumor terrain
Stefani clarifies the discovery: the combination of 14 proteins does not detect the tumor itself, but rather the biological environment conducive to its emergence.
“The main advance of this study lies in the application of artificial intelligence to examine more than 3,000 blood proteins and identify 14 of them that, together, form an indicator of predisposition to lung cancer, with the possibility of prediction for up to five years”, points out the expert.
According to the oncologist, this signature does not represent a definitive diagnosis, but rather a record of a continuous biological process. It includes inflammation, tissue repair and the reaction to damage that accumulates in the body, preceding the appearance of malignant cells.
“The protein signature does not guarantee the development of cancer, but rather reveals that the body is in a state of inflammation and repair of lung tissue, reacting to damage that, in combination with other variables, can favor tumor formation”, details Stefani.
This innovative approach begins to offer answers to a long-standing medical dilemma: why some heavy smokers never develop lung cancer, while individuals who have never smoked can be affected by the same disease.
While smoking and pollution are widely recognized risk factors, research suggests that it’s not just exposure to them that’s crucial. The determining factor is whether these triggers can activate a specific inflammatory response in each person’s lung tissue, detectable by the 14 identified proteins.
For Stefani, the protein signature reveals these individual biological distinctions, an aspect that the isolated history of smoking cannot highlight on its own.
The influence of pollution and inflammation on the onset of disease
In laboratory experiments with mice and cell cultures, scientists replicated what happens in the human lung when exposed to pollution. Inhaled particles activate defense cells, which release an inflammatory protein, making certain lung cells more susceptible to transforming into tumors, especially if they already have mutations linked to cancer.
This same triggering mechanism is also observed in conditions such as Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, suggesting a common inflammatory origin between these three pathologies.
“Pollution played a significant role in this analysis,” notes the oncologist.
Potential of the exam to expand screening
Currently, standard screening guidelines indicate a low-dose chest CT scan, performed annually, for individuals aged 50 to 80 years. This recommendation applies to those who have a smoking history of at least 20 pack-years — a metric that calculates the intensity and duration of the smoking habit — and who still smoke or have stopped smoking for less than 15 years.
This current criterion, however, excludes people who smoked for a short period, who gave up smoking a long time ago and, mainly, those who have never smoked. This last group has even shown an increase in lung cancer diagnoses, often associated with mutations in the EGFR gene, more prevalent in non-smokers.
If validated, the identification of these 14 proteins could revolutionize early detection. It would allow identifying, both within and outside current parameters, which individuals would benefit most from undergoing imaging exams at earlier stages.
The challenges and need for data validation
Despite the enthusiasm for the discovery, the scientists responsible for the study recommend caution. The “signature” of the 14 proteins is not yet available as a commercial laboratory test. For now, it remains a research result, requiring several years of rigorous validation before it becomes a reliable clinical test.
Stefani warns that prudence is equally essential when interpreting these results by the general public, outside the medical environment.
“This is a discovery that still requires validation, as individuals who participate in studies do not always reflect the entire population. Furthermore, it is still uncertain whether altering this protein signature actually reduces the likelihood of developing the disease. It is essential to highlight that a lower risk signature does not completely eliminate the risk, nor does it eliminate the need to avoid smoking or maintain other healthy habits”, emphasizes the cancer specialist.






